Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A malignant high-grade glioma that occurs during childhood in the central nervous system.
Biomarker and diagnostic research for pediatric high-grade glioma has been reported in the published literature.
2 clinical trials registered, 1 recruiting. Interventions under study include drug therapy and biologic therapy. Pipeline includes 1 PHASE1, 1 EARLY_PHASE1. Research is primarily sponsored by academic and government institutions.
63 publications have been identified in PubMed for pediatric high-grade glioma. Research spans Basic Science / Preclinical (32%), Review / Meta-Analysis (17%), and Gene Therapy / Novel Therapeutics (16%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 20 |
Data assembled from 3 of 12 sources · Last updated Sep 18, 2026, 10:22 AM UTC
Research summaries | 11 | 17% |
New treatment approaches | 10 | 16% |
Testing and diagnosis research | 7 | 11% |
Patient case studies | 7 | 11% |
Disease patterns and progression | 5 | 8% |
Other research | 2 | 3% |
Clinical study results | 1 | 2% |
Harper SD (2026). [PMID: 41504830](https://pubmed.ncbi.nlm.nih.gov/41504830/). *J Neurooncol*. [Review / Meta-Analysis]
Mayr L (2026). [PMID: 42143334](https://pubmed.ncbi.nlm.nih.gov/42143334/). *J Exp Clin Cancer Res*. [Gene Therapy / Novel Therapeutics]
Lindsay H (2026). [PMID: 41683962](https://pubmed.ncbi.nlm.nih.gov/41683962/). *Int J Mol Sci*. [Basic Science / Preclinical]
Kondapavulur S (2026). [PMID: 41941828](https://pubmed.ncbi.nlm.nih.gov/41941828/). *J Neurosurg Case Lessons*. [Case Report / Case Series]
Ford N (2026). [PMID: 42130628](https://pubmed.ncbi.nlm.nih.gov/42130628/). *Front Oncol*. [Gene Therapy / Novel Therapeutics]
Rogachevsky D (2026). [PMID: 40836108](https://pubmed.ncbi.nlm.nih.gov/40836108/). *Pediatr Res*. [Gene Therapy / Novel Therapeutics]
Dong M (2026). [PMID: 41896915](https://pubmed.ncbi.nlm.nih.gov/41896915/). *Cell Commun Signal*. [Basic Science / Preclinical]
Mignone C (2026). [PMID: 41274769](https://pubmed.ncbi.nlm.nih.gov/41274769/). *Neuroimaging Clin N Am*. [Review / Meta-Analysis]
Fernandez Garcia A (2026). [PMID: 41625177](https://pubmed.ncbi.nlm.nih.gov/41625177/). *J Extracell Biol*. [Diagnostic / Biomarker]
Martell E (2026). [PMID: 41825848](https://pubmed.ncbi.nlm.nih.gov/41825848/). *Cancer Lett*. [Review / Meta-Analysis]
AI-curated news mentioning pediatric high-grade glioma
Updated Sep 2, 2026
A recent study published in PubMed explores diffuse high-grade glioma with a gliomatosis cerebri pattern, which can mimic symmetric white matter disease. This research contributes to the understanding of glioma presentations and may impact diagnostic approaches.
Servier acquires Day One Biopharmaceuticals for $2.5 billion, enhancing its portfolio in childhood brain tumors. The acquisition includes Ojemda, which received FDA approval in 2024 and generated $155 million in sales for Day One in 2025.